Key Takeaways CORT posted Q2 EPS of $0.29, beating estimates, though revenues of$194.4M missed expectations.The company cut 2025 revenue guidance to $850-$900M from the prior $900-$950M range.CORT is advancing relacorilant and other candidates in multiple mid- and late-stage trials.Corcept Therapeutics (CORT) reported second-quarter 2025 earnings of 29 cents per share, which beat the Zacks Consensus Estimate of 23 cents. The company had reported earnings of 32 cents per share in the year-ago quarter.Revenu ...